Saliha Uysal

Dr. Saliha Uysal

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2015 in Angiology
Verified
Journal Article
Closed access
AKAdem Kucuk
Adem Kucuk
AUAli Ugur Uslu
Ali Ugur Uslu
SASevket Arslan
Sevket Arslan
SBSevket Balta
Sevket Balta
COCengiz Ozturk
Cengiz Ozturk
MKMehmet Kayrak
Mehmet Kayrak
The constriction of vessels due to atherosclerotic lesions causes hypoxia/ischemia and oxidative changes resulting in transformation of free albumin to ischemia-modified albumin (IMA) in the circulation and increased carotid intima–media thickness (cIMT). We investigated the reliability of IMA increase in evaluating atherosclerosis in patients with familial Mediterranean fever (FMF) compared with cIMT. Patients with FMF (n = 58) diagnosed by the Tel-Hashomer criteria in attack-free period and 38 healthy people were included in the study. Patient demographics as well as the clinical and laboratory characteristics of the healthy controls and patients with FMF were noted. The IMA levels and cIMT in patients with FMF were 0.30 ± 0.09 absorbance units (ABSUs) and 1.12 ± 0.27 mm, respectively, and in the control group, IMA levels and cIMT were 0.25 ± 0.07 ABSU and 0.74 ± 0.26 mm, respectively. The IMA levels and cIMT were significantly higher in patients with FMF than in controls (P = .020 and P < .0001, respectively). The IMA values showed positive correlation with cIMT in patients with FMF(r = .302, P = .041). Our results reveal that IMA—an oxidative stress marker—may be an indicator of atherosclerosis in patients with FMF. This finding deserves further investigation.

26 October 2021 in Drug and Chemical Toxicology
Verified
Journal Article
Closed access
IHIsmail Necati Hakyemez
Ismail Necati Hakyemez
MCMehmet Nuri Cevizci
Mehmet Nuri Cevizci
EAElif Aksoz
Elif Aksoz
KYKenan Yilmaz
Kenan Yilmaz
SUSaliha Uysal
Saliha Uysal
EAEren ALTUN
Eren ALTUN
The most important side effect of gentamicin (GM) is nephrotoxicity. p-Coumaric acid (PCA) is a phenolic compound that scavenges free radicals, reduces fibrosis, and tissue damage. This study investigates the protective effect of PCA on tissue damage and kidney function in gentamicin-induced nephrotoxicity (GIN). Thirty-five rats were separated into five groups and each group contained seven animals: control group, ethanol group, GM group, PCA group, and GM + PCA group. At the end of the seven-day treatment, the rats were sacrificed after blood and kidney tissue samples were taken. While serum urea, creatinine, and neutrophil gelatinase-associated lipocalin (NGAL) levels increased significantly in the GM group compared to the control, they showed a significant decrease in the GM + PCA group compared to the GM. Serum tumor necrosis factor-α (TNF-α) and tissue malondialdehyde (MDA) levels were significantly increased in the GM group compared to the control. While the tissue total oxidant status (TOS) and oxidative stress index (OSI) values of the GM group were significantly higher than the control, they showed a significant decrease in the GM + PCA group compared to the GM. In the histopathological examination, significant tubular necrosis and tubulointerstitial inflammation were detected in the proximal tubules in the GM group compared to the control, while a significant decrease was observed in the severity of these findings in the GM + PCA group compared to the GM. This study shows that PCA has biochemical and histopathological ameliorating effects on GIN in the rat model.

23 May 2025 in Medicine
Verified
Journal Article
Open access
AKAli Kirik
Ali Kirik
Omer ToprakOmer Toprak
Omer Toprak
HŞHacer Şen
Hacer Şen
SUSaliha Uysal
Saliha Uysal
SKsuleyman emre Kocyigit
suleyman emre Kocyigit
Özge Kama BaşcıÖzge Kama Başcı
Özge Kama Başcı
Zonulin (Zo) has recently been identified as a marker of intestinal permeability. It has previously been linked to type 2 diabetes mellitus, obesity, and cardiovascular disease; however, its role in chronic kidney disease (CKD) remains unclear. This study aimed to investigate the relationship between Zo and systemic inflammation (SI), endothelial dysfunction (ED), and renal function in CKD patients. One hundred sixty-three participants were enrolled in this study and divided into 2 groups (patient and control) according to the presence of CKD stage 3 to 5 not on dialysis. Circulating Zo levels have been investigated as markers of intestinal permeability. Furthermore, vascular cell adhesion molecule 1 (VCAM-1) and Interleukin-6 (IL-6) have been used as biomarkers for ED and SI assessments, respectively. A total of 104 patients with CKD (mean age: 58.9 ± 1.4) and 59 control subjects (mean age: 59.0 ± 1.1) were included, with similar age (P = .934) and sex (P = .196) between the groups. In the comparison analysis, plasma Zo levels in the CKD group (166.16 ± 53.54) were significantly higher than those in the control group (143.30 ± 60.92) (P < .001). In the correlation analysis, the serum Zo level showed a positive correlation with claudin-3 (R = 0.612, P < .001), IL-6 (R = 0.307, P < .001), and creatinine (R = 0.313, P < .001) and a negative correlation with glomerular filtration rate (GFR) (r = −0.320, P < .001). On the other hand, there was no correlation between circulating Zo and VCAM-1 levels (r = −0.139, P = .081). Additionally, according to linear regression analysis, Zo level was significantly associated with GFR after adjusting for age and systolic blood pressure (β = −0.918, P = .012). High serum Zo levels in patients with CKD reflect increased intestinal permeability and are associated with impaired renal function. Moreover, it was thought that Zo levels could be associated with SI; however, novel clinical studies are needed to elucidate their relationship with ED.


12 December 2022 in Nefrología (English Edition)
Verified
Journal Article
Open access
SUSaliha Uysal
Saliha Uysal
ATAysun Toker
Aysun Toker
KTKultigin Turkmen
Kultigin Turkmen
SKSuat Keskin
Suat Keskin
The cardiovascular risk has been increased in chronic kidney disease associated with chronic inflammation and atherosclerosis. Decoy receptor 3, is a member of the TNF receptor superfamily and associated with inflammation and atherosclerosis. The aim of our study is to determine the relationship, between serum DcR3 levels and inflammatory markers in patients with renal transplantation, those receiving dialysis treatment and cases with chronic renal failure that did not receive replacement therapy, and to evaluate their correlation with USG findings. A total of 150 patients aged between 22-86 years, consisting of 4 groups, namely renal transplantation, dialysis, predialysis chronic kidney disease and control groups, were included in the study. Serum decoy receptor 3, VCAM-1, ICAM-1 and IL-8 measured with ELISA method. Carotid intima-media thickness and presence of carotis arter plaque performed by ultrasound probe, non-invasively. All serum markers were higher in dialysis and pre-dialysis chronic kidney disease groups compared to renal transplant and control groups (p<0.05). Serum decoy receptor 3 level (median(min-max)) of renal transplant group (0.49ng/mL (0.19-1.65)) was higher than control group (0.35ng/mL (0.19-2.22)). There was no difference between patients receiving dialysis (0.89ng/mL (0.41-4.98)) and patients with pre-dialysis chronic kidney disease (0.71ng/mL (0.29-1.68)). There was no difference between patient groups in terms of the presence of plaque. Although renal transplantation provides a significant improvement in the inflammatory process, not return completely. Inflammatory process associated with uremic milieu may predispose to atherosclerosis in patients with pre-dialysis chronic kidney disease and hemodialysis patients.

29 July 2026 in Medicina
Verified
Journal Article
Open access
PDF file
USUmmu Serpil Sari
Ummu Serpil Sari
NTNermin Tepe
Nermin Tepe
AAAyla Solmaz Avcikurt
Ayla Solmaz Avcikurt
SUSaliha Uysal
Saliha Uysal
HBHILMI BOLAT
HILMI BOLAT
FEFigen Eşmeli
Figen Eşmeli
Background and Objectives: Circulating microRNAs (miRNAs) are emerging as accessible biomarkers for multiple sclerosis (MS). In experimental models, miR-221 and miR-222 have been linked to immune and Th17-related pathways, while interleukin-23 (IL-23) is a cytokine driving autoimmune inflammation. This observational study evaluated the expression of circulating miR-221/222 and serum IL-23 concentrations in treatment-naive adult patients with MS. Materials and Methods: This prospective, cross-sectional case–control study included 43 untreated adult patients with MS (36 with relapsing–remitting MS and 7 with primary progressive MS) and 37 healthy controls. Demographic features, Expanded Disability Status Scale (EDSS) scores, magnetic resonance imaging involvement, initial symptoms, serum IL-23 concentration, and miR-221/222 expression were recorded. Total RNA, including small RNAs, was isolated; complementary DNA was synthesized by reverse transcription from RNA templates; and reverse transcription–quantitative real-time PCR (RT-qPCR) was performed using RNU6-2 as the endogenous small RNA reference. Individual ΔΔCt values were specified as the primary inferential scale, while 2−ΔΔCt fold-change was retained only for descriptive reporting. Results: The relative expression (2−ΔΔCt) of miR-221 and miR-222 was higher in patients than in controls. Within the patient group, miR-221 and miR-222 relative expression did not differ by age, sex, EDSS, time since MS diagnosis, MRI involvement area, or initial symptoms. No statistically significant difference in IL-23 levels was observed between the patient and control groups. Conclusions: The presence of unaltered IL-23 levels alongside significantly elevated miR-221 and miR-222 expressions in treatment-naive MS patients during the remission phase suggests their potential utility as biomarkers for immune regulation. Given the cross-sectional design of this study, no causal or regulatory relationship between miR-221/222 and IL-23 can be inferred.